Company Interview / Telix guides to $1B revenue amid $5M loss

Key Points:

Revenue climbs 56% as Telix Pharmaceuticals (ASX:TLX) surpasses guidance, but records 1H net lossGlobal strategic expansion and two new product launches expected to drive revenue growthFocus on reinvestment, with three drugs in pivotal phase three trials set for 2026/2027 milestonesCompany targets margin improvement via vertical integration and self-distribution

Telix Pharmaceuticals (ASX:TLX) records a 1H net loss of $5.3 million USD, despite seeing its annual revenue rise by 56% to just under $804 million USD, surpassing previous guidance. Christian Behrenbruch emphasises that the current focus for the company is on reinvestment, particularly into research and development, with three drugs in phase three clinical trials expected to mark significant commercial milestones by 2026 and 2027. He states 2028 will be a pivotal year, as Telix prepares for a pre-commercial launch of its therapeutics business, paving the way for a greater emphasis on profitability.

Behrenbruch points to strong performance from Telix’s two currently approved prostate cancer products in the US as key drivers for projected revenue of $950 to $970 million USD for the coming year. Global expansion, including recent European approvals and reimbursement, is expected to boost ex-US revenue, with two new product approvals anticipated this year. Following regulatory setbacks in the US, Behrenbruch insists momentum remains strong, referencing recent submissions in both the US and EU for a glioblastoma (brain cancer) imaging product.

On margins, Behrenbruch highlights vertical integration, following Telix’s acquisition of LLS Radio Pharmacies, as central to sustaining and improving gross margins. He identifies the multi-product strategy and increasing self-distribution as critical to future growth and operational control.